Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 13Unknown 2No longer available 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Non-small Cell Lung Cancer Harboring ROS1 Rearrangement 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × ceritinib × Clear all
NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Sungkyunkwan University

Unknown
4,724 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01964157 2019-01-11

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Yonsei University

Phase 2 Unknown
32 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡